BR112022012362A2 - Anticorpos cd163 ou proteínas de ligação - Google Patents

Anticorpos cd163 ou proteínas de ligação

Info

Publication number
BR112022012362A2
BR112022012362A2 BR112022012362A BR112022012362A BR112022012362A2 BR 112022012362 A2 BR112022012362 A2 BR 112022012362A2 BR 112022012362 A BR112022012362 A BR 112022012362A BR 112022012362 A BR112022012362 A BR 112022012362A BR 112022012362 A2 BR112022012362 A2 BR 112022012362A2
Authority
BR
Brazil
Prior art keywords
porcine
antibodies
antigen
binds
amino acid
Prior art date
Application number
BR112022012362A
Other languages
English (en)
Portuguese (pt)
Inventor
Owen Charles
Abdelaali Benchaoui Hafid
TAIT-BURKARD Christine
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of BR112022012362A2 publication Critical patent/BR112022012362A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022012362A 2019-12-24 2020-12-24 Anticorpos cd163 ou proteínas de ligação BR112022012362A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
BR112022012362A2 true BR112022012362A2 (pt) 2022-09-06

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012362A BR112022012362A2 (pt) 2019-12-24 2020-12-24 Anticorpos cd163 ou proteínas de ligação

Country Status (13)

Country Link
US (1) US20230203185A1 (enExample)
EP (1) EP4081542A1 (enExample)
JP (1) JP7702952B2 (enExample)
KR (2) KR20260098023A (enExample)
CN (2) CN115151569B (enExample)
BR (1) BR112022012362A2 (enExample)
CL (1) CL2022001706A1 (enExample)
CO (1) CO2022010294A2 (enExample)
DO (2) DOP2022000136A (enExample)
GB (1) GB201919294D0 (enExample)
MX (1) MX428622B (enExample)
PE (1) PE20230384A1 (enExample)
WO (1) WO2021130502A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
JP2026519901A (ja) * 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Ｃｄ１６３結合複合体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076501A2 (en) * 2001-03-26 2002-10-03 Hemosol Inc. Blood cell production via activation of the hemoglobin scavenger receptor
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20160158368A1 (en) * 2014-10-31 2016-06-09 Therapure Biopharma Inc. Methods and compositions for the treatment of histiocytosis
HRP20240908T1 (hr) * 2015-08-06 2024-10-25 The Curators Of The University Of Missouri Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
JP2023508674A (ja) 2023-03-03
CO2022010294A2 (es) 2022-10-31
US20230203185A1 (en) 2023-06-29
PE20230384A1 (es) 2023-03-06
CN115151569A (zh) 2022-10-04
KR20260098023A (ko) 2026-06-25
CN121873247A (zh) 2026-04-17
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CL2022001706A1 (es) 2023-05-26
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
KR20220119147A (ko) 2022-08-26
CA3162664A1 (en) 2021-07-01
MX428622B (es) 2025-11-13
CN115151569B (zh) 2026-05-01
EP4081542A1 (en) 2022-11-02
JP7702952B2 (ja) 2025-07-04
GB201919294D0 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
CL2022001706A1 (es) Anticuerpos o proteínas de unión a cd163.
CL2023001888A1 (es) Anticuerpos multiespecíficos con especificidad para il-4r e il-31.
BR112021016955A2 (pt) Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
EA202090247A1 (ru) Антитела против cd166 и их применения
BR112021024553A2 (pt) Molécula de ligação específica para cd73 e uso de molécula de ligação
BR112023000826A2 (pt) Anticorpo anti-ctla-4 e uso do mesmo
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BRPI0509847B8 (pt) anticorpo que se liga à p-seletina, seu método de preparo e uso, vetor, composição e kit
BR112014009030A2 (pt) anticorpo de ligação a antígenos múltiplos estável
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
MX2021013441A (es) Molecula de union a antigenos, composicion farmaceutica y metodo.
BR112022024084A2 (pt) Receptores de antígeno quiméricos específicos para p95her2 e usos dos mesmos
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
BRPI0414515A (pt) moléculas de ligação terapêuticas
JP2019504014A5 (enExample)
BR112022004603A2 (pt) Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
BR112022001017A2 (pt) Anticorpo monoclonal anti-vegf humanizado
BR112014002929A8 (pt) Novos anticorpos contra fosforilcolina
BR112023021426A2 (pt) Anticorpos de ligação a trop2 e usos dos mesmos
BR112022021893A2 (pt) Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune
BR112022011323A2 (pt) Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos
CO2024017548A2 (es) Anticuerpos para la toxina similar a la enteritis necrótica b

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ECO ANIMAL HEALTH LTD. (GB)